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Abstract
Background: Canonical serine protease inhibitors commonly bind to their targets through a rigid loop stabilised by an
internal hydrogen bond network and disulfide bond(s). The smallest of these is sunflower trypsin inhibitor (SFTI-1), a potent
and broad-range protease inhibitor. Recently, we re-engineered the contact b-sheet of SFTI-1 to produce a selective
inhibitor of kallikrein-related peptidase 4 (KLK4), a protease associated with prostate cancer progression. However,
modifications in the binding loop to achieve specificity may compromise structural rigidity and prevent re-engineered
inhibitors from reaching optimal binding affinity.
Methodology/Principal Findings: In this study, the effect of amino acid substitutions on the internal hydrogen bonding
network of SFTI were investigated using an in silico screen of inhibitor variants in complex with KLK4 or trypsin.
Substitutions favouring internal hydrogen bond formation directly correlated with increased potency of inhibition in vitro.
This produced a second generation inhibitor (SFTI-FCQR Asn14) which displayed both a 125-fold increased capacity to
inhibit KLK4 (Ki = 0.038660.0060 nM) and enhanced selectivity over off-target serine proteases. Further, SFTI-FCQR Asn14
was stable in cell culture and bioavailable in mice when administered by intraperitoneal perfusion.
Conclusion/Significance: These findings highlight the importance of conserving structural rigidity of the binding loop in
addition to optimising protease/inhibitor contacts when re-engineering canonical serine protease inhibitors.
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Introduction
Prostate cancer is the most commonly diagnosed male cancer in
western countries, accounting for more than 32,000 deaths last
year in the United States alone [1]. Although current treatments
for localized prostate cancer are highly successful, less than one
third of patients with metastatic disease survive five years following
diagnosis [1]. This emphasises the urgent need for effective
treatments for patients suffering from late stage disease. Prostate
cancer is primarily detected using serum levels of kallikrein-related
peptidase 3 (KLK3, prostate-specific antigen, PSA), which is the
established biomarker for diagnosis and prognosis [2]. KLK3
belongs to the kallikrein-related peptidase (KLK) multi-gene family
which encodes fifteen homologous serine endopepti dases with
trypsin or chymotrypsin-like substrate specificity. It is well
documented that KLK proteases significantly contribute to several
important (patho)physiological functions [3]. Consequently, there
is a growing interest in the utility of KLKs in certain pathologies as
biomarkers and therapeutic targets [4,5], particularly in hormone-
dependent cancers [6].
One KLK of interest, KLK4, is principally expressed in basal
and secretory cells of the prostate gland and is commonly
overexpressed in malignant prostate tumours [7,8]. Recent studies
indicate that the proteolytic activities of KLK4 closely align with
events central to cancer development and progression. Firstly,
KLK4 has been shown to degrade components of the extracellular
matrix in vitro [9], as well as cleave insulin-like growth factor
binding protein 3-6 [10] and urokinase plasminogen activator
receptor [11]. Secondly, cell culture experiments have demon-
strated that KLK4 enhances a diverse array of strongly
tumourigenic functions. Of note, KLK4 stimulates protease-
activated receptors 21 and 22 which are also overexpressed in
prostate cancer, resulting in cytoskeletal remodelling and increased
cell migration and proliferation [12,13,14]. These findings
complement earlier studies which found overexpression of
KLK4 was associated with an epithelial-to-mesenchymal transi-
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tion in prostate cancer cells [8] and that KLK4 may modulate
interactions between tumour cells and osteoblasts in the develop-
ment of bone metastases [15]. Therefore, targeted inhibition of
KLK4 may present an avenue to new treatments for advanced
prostate cancer.
It has previously been reported that the naturally occurring
sunflower trypsin inhibitor (SFTI-1) inhibits KLK4 [16], in
addition to known targets such as trypsin [17], cathepsin G [18]
and matriptase (ST14/MT-SP1) [19]. SFTI-1 is a 1.4 kDa cyclic
Bowman-Birk serine protease inhibitor (BBI) isolated from
sunflower (Helianthus annuus) seeds. Its three-dimensional structure
in complex with trypsin [17] reveals a dual anti-parallel b-sheet
arrangement stabilized by a disulfide bridge and an extensive
internal hydrogen bonding network [20]. SFTI-1 binds to target
proteases by an extended b-sheet across the P1-P4 residues to form
a tight binding complex (trypsin/SFTI-1 Ki = 0.1 nM) [21]. This
mode of binding is not only common to canonical serine protease
inhibitors [22] but forms the basis of protein substrate and
inhibitor recognition across all families of proteases [23].
Another important feature of SFTI-1 is that its scissile bond
(P1–P19) can be cleaved and reformed with an equilibrium of 1:9
in favour of the intact bond [24]. This phenomenon is evident in at
least 19 convergently evolved serine protease inhibitor families
[25] and is referred to as ‘standard’ or Laskowski mechanism of
inhibition [26,27]. Standard mechanism binding loops are typified
by a high degree of rigidity due to an internal network of
stabilising hydrogen and disulfide bond(s). This has particular
significance to inhibitor function; not only does it allow for a lower
entropic debt upon protease binding [28], it also permits
formation of an acyl-enzyme intermediate with largely unchanged
conformation [29,30]. As the products of hydrolysis are still
associated with the protease, resynthesis of the peptide bond is
more favoured than the intermolecular reaction with lower local
reactant concentrations [30,31].
To harness the favourable structural features of SFTI-1 and
redirect inhibition towards KLK4, the contact b-sheet of SFTI was
recently re-engineered using a sparse matrix peptide library to
guide amino acid substitutions. The resulting inhibitor, SFTI-
FCQR (P1 Lys to Arg, P2 Thr to Gln and P4 Arg to Phe)
selectively inhibited KLK4 (Ki = 3.5960.28 nM) and uniformly
showed low inhibition of other SFTI-1 targets and closely related
KLKs [16]. However, the constrained geometry of SFTI prevents
the use of linear peptide libraries to optimise interactions beyond
the P1–P4 residues, while producing a synthetic SFTI library is
prohibitively costly and time consuming. Therefore, it is more
practical to screen a virtual library of SFTI-FCQR variants.
Conventional in silico scoring functions rely on docking
algorithms that treat the bonds of the ligand and receptor as rigid
or semi-flexible to reduce the computational costs. However, these
methods only have an acceptable degree of accuracy when
considering ligands with few conformational states [32,33].
Molecular dynamics (MD) offers a solution to the problem of
structural flexibility. Indeed, several studies have successfully used
MD to predict inhibitor performance, yielding new lead
compounds or improving existing inhibitors [34,35]. Recent
advances in graphics card processors (GPUs) [36] have enabled
GPU-implementation of MD algorithms, making them more
accessible for flexible receptor-ligand analysis.
Here the GPU-implemented MD algorithms ACEMD [37] and
NAMD [38] are used to explore the SFTI-1/trypsin complex and
analyse an in silico library of SFTI-FCQR variants. Increased
internal hydrogen bond frequency showed a high degree of
accordance with enhanced inhibition in vitro. The most favourable
substitution produced a second generation inhibitor with a binding
affinity for KLK4 similar to that of SFTI-1 for trypsin while
selectivity was markedly improved. These findings underline the
importance of binding loop rigidity in canonical serine protease
inhibitors and the need to maintain structural stability when
modifying compounds of this class.
Methods
Protein expression and purification
Recombinant KLK4 and KLK14 were produced using Sf9
insect cell expression constructs as previously reported [14,16].
These expression vectors generate the complete KLK amino acid
sequence followed by a V5 epitope (GKPIPNPLLGLDST) and
polyhistidine tags. Pro-KLKs were purified from conditioned
media using Ni2+-nitrilotriacetic acid agarose (Qiagen) according
to the manufacturer’s instructions. After confirming the identity of
purified proteins by Western blot analysis, pro-KLKs were
aliquoted and stored at 280uC.
Molecular dynamics
SFTI-FCQR variant/KLK4 complexes were generated by
overlay of KLK4 (PDB ID 2BDG) and the trypsin/SFTI-1
complex (PDB ID 1SFI) in SPDBV v4.01 (RSMD 0.96 A˚) [39]
while mutations were made in YASARA Dynamics 9.12.13 [40].
Systems were solvated with TIP3P water and neutralized by Na+/
Cl2 counterions to a final concentration of 100 mM in VMD
1.8.7 [41]. This generated systems of approximately 28000 atoms
including 9000 water molecules.
Each protease–inhibitor complex was equilibrated using a
stepwise relaxation procedure. In the first stage, all heavy-atoms
were harmonically restrained with a force constant of 2 kcal/
(mol A˚2) before a conjugate gradient minimization of 5000 steps
was applied using NAMD 2.6 [38] and CHARMM27 force fields
parameters. This was followed by heating to 298 K before
simulating 500 ps under NPT conditions with periodic boundary
conditions. A Langevin thermostat with a damping coefficient of
0.5 ps21 was used to maintain the system temperature. The system
pressure was maintained at 1 atm using a Langevin piston
barostat. The particle mesh Ewald algorithm was used to compute
long-range electrostatic interactions at every time step and non-
bonded interactions were truncated smoothly between 7.5 A˚ and
9 A˚. All covalent hydrogen bonds were constrained by the
SHAKE algorithm (or the SETTLE algorithm for water),
permitting an integration time step of 2 fs. For the second stage,
the restraints were retained on the protease and inhibitor a-
carbons (Ca) only, while all constraints were released in the third
stage.
Three independent production runs of 5 ns were carried out for
each system using ACEMD [37]. These simulations were
performed under NVT with otherwise identical force field and
simulation parameters as above. Coordinates were saved every
500 simulation steps producing 5000 frames per run. Analyses
were performed using VMD 1.8.7 with hydrogen bond lengths
and angles set to 40u and 3.3 A˚ respectively, chosen to align with
the reported trypsin/SFTI-1 complex [17].
Synthesis of SFTI variants
All reagents were obtained from Auspep and all solvents from
Merck unless stated otherwise. Inhibitors were synthesised as
linear peptides on 2-chlorotrityl resin (1.3 mmol/g) derivatized
with 0.9 mmol/g of the first residue, Ser (P19). Coupling of the
following nine residues was achieved using four-fold excess of
Fmoc-protected amino acids dissolved in 0.25 M each of 2-
(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluoropho-
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sphate (HBTU), 1-hydroxybenzo-triazole (HOBt), and N,N-diiso-
propylethylamine (DIPEA) in N,N-dimethylformamide (DMF).
Fmoc protecting groups were removed by incubation in 50%
piperidine and 5% 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in
DMF. Addition of the final four residues occurred as above, except
that DMF was replaced with ‘magic mix’ solvent to prevent
aggregation (Zhang et al., 1994). This contained equal parts of DMF,
DCM and N-methyl-2-pyrrolidone (NMP) or DMF, toluene and
NMP for coupling and Fmoc removal respectively.
Linear peptides were liberated from the solid support by
successive changes of 0.5% trifluoroacetic acid (TFA) in
dichloromethane (DCM). Cyclisation of the peptide backbone
was achieved in solution using 125 mM each of 1-hydroxy-7-aza-
benzotriazole (HOAt) and benzotriazol-1-yl-oxytripyrrolidinopho-
sphonium hexafluorophosphate (PyBOP) dissolved in DMF
containing 0.25 M DIPEA. Cyclization proceeded for 48 hr
before dilution with an equal volume of DCM and extraction
with H2O to remove residual reactants. Side chain protecting
groups were removed from the dry product by cleavage for 2 hr in
93.75% TFA, with scavengers; 1.25% triisopropylsilane (TIS),
1.25% H2O and 3.75% thioanisole. Cleaved peptides were
purified from remaining synthetic by-products by reverse phase
HPLC (rp-HPLC) across a gradient of 20-100% isopropanol using
a Jupiter 4 m Proteo 90A C-18 column (Phenomenex). Formation
of the internal disulphide bond was achieved by overnight stirring
in an aqueous redox buffer (150 mM Tris-HCl pH 8.0, 1 mM
EDTA, 10 mM reduced glutathione, 1 mM oxidised glutathione)
while monitoring the reaction progress by MALDI-TOF mass
spectrometry. Completed SFTI variants were purified, lyophilised
and stored at -20uC.
Synthesis of peptide substrates
Peptide para-nitroanilide (pNA) substrates were synthesised on p-
phenylenediamine (Sigma-Aldrich) derivatised 2-chlorotrityl resin
(1.3 mmol/g) according to previously described methods [16,42].
Completed substrates were purified by rp-HPLC, validated by
MALDI-TOF/MS and lyophilised before storage at 220uC.
Inhibition assays
Bovine b-trypsin, bovine a-chymotrypsin and human thrombin
were obtained from Sigma while KLK12 and matriptase were
from R&D Systems. Increasing concentrations of inhibitors were
incubated with various concentration of protease (final concen-
trations: KLK4, 1.5 nM; KLK12, 15 nM; KLK14, 2 nM; trypsin,
1 nM; matriptase, 4 nM; thrombin, 25 nM; a-chymotrypsin
25 nM) for 20 min in 200 ml assay buffer (100 mM Tris-HCl,
100 mM NaCl2, 0.005% triton-X, pH 8.0). Assays with thrombin
and trypsin included 10 mM CaCl2. Enzyme activity was initiated
by addition of substrate in 100 ml assay buffer (final concentration
100 mM; see Table 2). The rate of hydrolysis was measured at
405 nm over 7 min and was linear over this period. The extended
assay period allowed for identification of inhibitors that were
degraded. For SFTI-FCQR Asp14, Ki was determined by
inhibition at various substrate concentrations using the compet-
itive inhibition model and non-linear regression in Prism 5
(GraphPad Software Inc). The Ki for this inhibitor was also
determined using the Morrison equation for tight binding
inhibitors [43] (FVQR-pNA KM = 679.96113.1 mM [16]) and
non-linear regression in Prism 5. Both methods produced
comparable results (Table 2) and subsequent Ki values were
determined with the Morrison method. Since SFTI-FCQR Asn14
had an IC50 below the concentration of KLK4, assays for this
inhibitor were repeated with 0.15 nM KLK4 over 2 hr. The kon
and koff were determined from the lag phases and steady state of
inhibition as previously described [44] using assay conditions as
above and 500 mM substrate. Assays for inhibition of fibrinogen
proteolysis used the same buffer and enzyme concentrations as
above with 7 mM fibrinogen substrate. Proteolysis proceeded for
15 min (trypsin), 90 min (KLK4 and 14) or 180 min (KLK12)
before termination by boiling in SDS-PAGE sample buffer.
Proteolysis fragments were separated on 10% polyacrylamide gels.
Stability of SFTI variants in cell culture
The half-life in cell culture for SFTI-FCQR Asn14 and SFTI-
FCQR Lys14 was determined using previously described methods
[16]. Briefly, monolayers of LNCaP, 22Rv1 and PC3 cells were
established in RPMI 1640 medium supplemented with 10% foetal
calf serum (HyClone), 100 U/ml penicillin (Invitrogen) and
100 mg/ml streptomycin (Invitrogen). Cells were treated 61 mM
inhibitor (SFTI-FCQR Asn14 or SFTI-FCQR Lys14) in fresh
serum-containing media. Samples of media were taken at 24 hr
intervals and boiled at 97uC for 15 min to denature serum protein.
Residual inhibition by SFTI-FCQR variants was determined in
competitive kinetic assays (as above), adding a volume of media to
give 10 nM SFTI-FCQR Asn14 or 25 nM SFTI-FCQR Lys14 at
0 hr. Media without inhibitor was used to adjust for any
endogenous media inhibition and data represent the mean 6
SEM of three triplicate experiments.
Assessment of bioavailability in mice
Stability and bioavailability of SFTI-FCQR Asn14 in vivo was
assessed in BALB/cFoxn1/Arc mice by oral, intravenous and
intraperitoneal delivery (3 mg/kg). Inhibitor was dissolved in PBS
at a concentration of 0.6 mg/ml prior to dosing. Serum levels of
SFTI-FCQR Asn14 were subsequently measured by Liquid
Chromatography-Mass Spectrometry (LC-MS) at Tetra Q
laboratories (University of Queensland, Brisbane, Australia). This
study was carried out in strict accordance to the recommendations
of the Australian Code of Practice for the Care and Use of
Animals for Scientific purposes (7th edition 2004) and the protocol
was approved by the University of Queensland Animal Ethics
Committee (ABS group) which assigned the project approval code
TetraQ/479/09/Bluebox. All efforts were made to minimize
suffering by experimental animals.
Results
Molecular dynamics reveals a reduction in internal
hydrogen bonds for SFTI-FCQR Asp14 compared to SFTI-1
The contribution of various SFTI-1 residues to inhibitor rigidity
and complex stability was examined by molecular dynamics
simulations on the trypsin/SFTI-1 complex (Figure 1A; PDB ID
1SFI). Post-simulation analysis of the internal hydrogen bond
network agreed with the reported structure [17] regarding the
reactive loop while differing in the side loop (Figure 1B). Most
notably, rather than acting solely as a proton acceptor for the
backbone amide nitrogen atom of Arg2, the Asp14 side chain more
often formed hydrogen bonds with the guanidino nitrogens of
Arg2. These hydrogen bonds are evident in 20% of conformations
in a solution structure of SFTI-1 [21]. Additionally, it appeared
that the Asp14-Arg2 side chain hydrogen bonds subtly altered the
backbone conformation meaning that the hydrogen bond between
the amide of Gly1 and carbonyl oxygen of Phe12 seen in the crystal
structure was infrequent.
Consistent with this, the Ca RMSD values of SFTI-1 from the
MD trajectory showed that the reactive loop conformation closely
aligned with the starting structure while the side loop deviated
markedly (Figure 2A). Determining Ca RMSD values using the
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simulation average structure as a reference indicated that although
the change in conformation in the side loop varied from the SFTI-
1 structure, the new conformation was stable (Figure 2B and C).
The most rigid backbone atoms were found in residues that
formed an extended b-sheet with trypsin (P3-P1) and as a result
were flanked by both internal and intermolecular hydrogen bonds.
Overall, the average number of internal hydrogen bonds for
trypsin/SFTI-1 was 7.0060.07, equivalent to the total number
identified in the crystal structure.
Previously, SFTI-1 was re-engineered to produce a selective
KLK4 inhibitor (SFTI-FCQR Asp14) by optimising protease/
inhibitor interactions [16]. To examine the impact of modifying
the contact b-sheet of SFTI on the distribution of internal
hydrogen bonds, corresponding simulations were performed on
KLK4 (PDB ID 2BDG) in complex with a model of SFTI-FCQR
Asp14. The resulting analysis suggested a marked reduction
(mean = 3.7060.11) and rearrangement of the internal hydrogen
bond network compared to SFTI-1 (Figure 1B). In the reactive
loop, the side chain Thr4-Ser6 hydrogen bond was replaced by one
between the carbonyl oxygen of Gln4 and the amide of Ser6 while
Asp14 in the side loop no longer formed any recurrent internal
hydrogen bonds. Perhaps as a result of the latter, the backbone
hydrogen bonding pairs Phe2-Phe12 (Arg2-Phe12 in SFTI-1) and
Gly1-Phe12 seen in the trypsin/SFTI-1 structure were again
prevalent. These changes in internal hydrogen bonding pattern
were accompanied by an altered conformation that poorly aligned
with the SFTI-1 starting structure (Figure 2A) and reduced rigidity
across the scaffold (Figure 2B and C).
Substitution at Asp14 alters internal hydrogen bonding in
SFTI
Inspection of the KLK4/SFTI-FCQR Asp14 simulation trajec-
tories revealed that Asp14 showed a high level of disorder and was
too far from KLK4 to make contact and thus appeared not to
contribute to complex stability. This suggested that substitution of
Asp14 could present an opportunity to restore the internal
hydrogen bonding network of the inhibitor. Structural imperatives
restricted the opportunities for further replacements around the
SFTI backbone and so no further substitutional analyses of these
positions were undertaken. Accordingly, a library of SFTI-FCQR
Figure 1. Representation of a trypsin/SFTI-1 complex and internal hydrogen bonding within SFTI variants during MD. Ribbon plot of
SFTI-1 in complex with trypsin (A) with b-sheets and a-helices coloured in yellow and blue respectively, excluding SFTI-1 which is displayed in
magenta. The residues of the catalytic triad of trypsin and the P1 Lys of SFTI-1 are shown in stick models with carbon in green, nitrogen in blue and
oxygen in red. The structure of SFTI variants are shown in ball and stick 2D model with intramolecular hydrogen bond networks for (B) SFTI-1, (C)
SFTI-FCQR Asp14 and (D) SFTI-FCQR Asn14. Amino acids are labelled with one letter code and residue number in subscript while the frequency of
hydrogen bonds per residue is in brackets (rounded to nearest tenth). Carbons, oxygen, nitrogen and sulphur are represented by gray, red, blue and
yellow respectively while hydrogens are excluded for clarity. Bond lengths and angles are intentionally unrealistic to enable easy viewing of hydrogen
bonds, represented by dotted green line. Only hydrogen bonds occurring in more than 50% of trajectory frames are shown. Data is represented as
mean from three independent 5 ns MD trajectories.
doi:10.1371/journal.pone.0019302.g001
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variants containing all naturally occurring amino acids (excluding
cysteine) at residue 14 was simulated followed by hydrogen bonds
analysis (Table 1). The frequency of internal hydrogen bonds in
the starting structure (SFTI-FCQR Asp14) was only slightly above
the median. Further, modifying residue 14 had a considerable
effect on the internal hydrogen bond network across the nineteen
SFTI-FCQR variants, ranging from 2.2860.07 (His14) to
4.2960.31 (Asn14) average hydrogen bonds. In contrast, these
substitutions had little effect on the number of intermolecular
hydrogen bonds, producing a slight decrease for the majority of
variants. To verify these in silico results, six variants representative
of the diverse residue side chains and the number of hydrogen
bonds were synthesised: Asn14 (amide), Tyr14 (aromatic), Lys14
(basic), Gly14 (flexible), Ala14 (less flexible) and Ser14 (alcohol).
These were screened against KLK4 in vitro to determine respective
inhibition constants (Table 2).
SFTI-FCQR Asn14, predicted to have the most internal
hydrogen bonds, was also the most potent KLK4 inhibitor with
a Ki of 0.038660.0060 nM, exceeding that of SFTI-1 for
trypsin (Ki = 0.1 nM). Furthermore, there was a consistent
correlation between increasing number of internal hydrogen
bonds during MD simulation and decreasing inhibition
constants in vitro (Figure 3). However, it should be noted that
SFTI-FCQR Lys14 assays were carried out immediately after
addition of inhibitor since this variant was degraded after
prolonged incubation with KLK4 (tK= 56.366.2 minutes).
This may reflect the introduction of a second potential cut site
for trypsin-like proteases (Lys) on the side loop of SFTI.
Although the Arg5-Ser6 scissile bond can be cleaved on SFTI
without detrimental effect, the side loop does not have the
features of a canonical loop and cleavage of the Gly1-Lys14
peptide bond may be irreversible.
Examining the internal hydrogen bonding network of SFTI-
FCQR Asn14 revealed that substitutions at position 14 influenced
their frequency and distribution across the entire scaffold
(Figure 1C). In the side loop, the Asn14 side chain formed
Figure 2. RMSD analysis for SFTI variants during MD. RMSD values between Ca of SFTI-1, SFTI-FCQR Asp14 and SFTI-FCQR Asn14 during MD
and the (A) SFTI-1 starting structure or (B) calculated average simulation structures. (C) Ribbon plot showing the average simulation structures
coloured according to Ca RMSD from low to high as blue, purple, magenta, orange, and red, labelled with odd residue numbers. Data is represented
as mean from three independent 5 ns MD trajectories.
doi:10.1371/journal.pone.0019302.g002
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Table 1. In silico Internal Hydrogen Bond Analysis of SFTI-FCQR Residue 14 Variants.
SFTI variant
Internal Hydrogen Bonds
(Mean ± SEM)
% Change from
SFTI-FCQR Asp14
Intermolecular Hydrogen
Bonds (Mean ± SEM)
% Change from SFTI-FCQR
Asp14
SFTI-FCQR Asn14 4.6860.086 26.5 8.4660.10 2.1
SFTI-FCQR Val14 4.2660.14 15.1 8.1760.18 0.1
SFTI-FCQR Tyr14 4.0760.24 9.9 8.2260.30 20.7
SFTI-FCQR Met14 3.9860.12 7.6 8.1160.20 22.0
SFTI-FCQR Lys14 3.9160.47 5.6 8.1160.17 22.1
SFTI-FCQR Phe14 3.8960.15 5.1 7.5860.08 28.5
SFTI-FCQR Ile14 3.8560.43 4.2 7.3060.35 211.8
SFTI-FCQR Asp14 3.7060.11 0 8.2860.19 0
SFTI-FCQR Gly14 3.6760.30 20.9 7.8660.17 25.1
SFTI-FCQR Pro14 3.6660.43 21.0 6.4960.23 221.7
SFTI-FCQR Glu14 3.5960.50 23.0 7.8360.36 25.5
SFTI-FCQR Arg14 3.5160.51 25.1 7.6560.04 27.6
SFTI-FCQR Gln14 3.3660.25 29.2 7.5260.14 29.2
SFTI-FCQR Leu14 3.3360.26 210.0 8.1160.17 27.7
SFTI-FCQR Trp14 3.1260.22 215.6 7.9260.36 24.3
SFTI-FCQR Thr14 2.9360.093 221.0 7.3460.06 211.3
SFTI-FCQR Ala14 2.8960.085 221.8 7.2560.16 212.4
SFTI-FCQR Ser14 2.5660.048 230.8 7.5260.10 29.1
SFTI-FCQR His14 2.2860.068 238.2 8.07 6 0.11 22.5
doi:10.1371/journal.pone.0019302.t001
Table 2. Inhibitory Properties of SFTI-1, SFTI-FCQR and SFTI-FCQR Residue 14 Variants.
Enzyme Inhibitor IC50 (nM) Ki (nM)
Morrison
Ki (nM)
Theoretical
Mass
Determined
Mass
Substrate
(100 mM)
KLK4 SFTI-FCQR Asn14 0.063560.0024 - 0.038660.0060 1559.75 1560.40 FVQRpNA
SFTI-FCQR Tyr14 3.476 0.20 - 2.5560.43 1610.77 1610.56
SFTI-FCQR Lys14 6.0760.13 - 3.5660.27 1573.80 1574.93
SFTI-FCQR Asp14 7.9761.08 [16] 3.6260.26 3.8960.40 1560.73 1559.94
SFTI-FCQR Gly14 14.7461.089 - 10.3962.87 1502.73 1504.77
SFTI-FCQR Ala14 26.2360.85 - 18.316 3.36 1516.74 1517.99
SFTI-FCQR Ser14 29.2361.081 - 21.24 63.81 1532.74 1533.94
SFTI-1 221610.1 [16] - - 1514.75 1514.84
KLK14 SFTI-FCQR Asp14 1506637.1 [16] - - - - Ac-GSLR-pNA
SFTI-FCQR Asn14 2516 21.9 - - - -
b-Trypsin SFTI-FCQR Asp14 40646109 [16] - - - - BAPNA
SFTI-FCQR Asn14 21786145 - - - -
SFTI-1 - 0.1 [17] - - -
Matriptase SFTI-FCQR Asn14 .10,000 - - - - Bz-FVRpNA
SFTI-1 - 0.92 [19] - - - N-t-Boc-QAR-AMC
Thrombin SFTI-FCQR Asn14 .10,000 - - - - Bz-FVRpNA
SFTI-1 - 5050 [19] - - - N-t-Boc-LRR-AMC
Chymotrypsin SFTI-FCQR Asn14 .10,000 - - - - WpNA
SFTI-1 - 23006100 [51] - - - N-succinyl-
AAPPpNA
Amino acids are represented by the one letter code.
doi:10.1371/journal.pone.0019302.t002
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hydrogen bonds with the backbone amides of Phe2 and Gly1 with
similar prevalence as seen for corresponding residues in SFTI-1.
In comparison to SFTI-FCQR Asp14, the hydrogen bonds
between Phe2-Phe12 and Gly1-Phe12 were similarly frequent
while a further hydrogen bond was prevalent between the
backbone amide of Asn14 and the carbonyl oxygen of Phe12.
Overall, it appeared that changes in the hydrogen bonding
pattern in the side loop of SFTI-FCQR Asn14 restored the
frequency of the hydrogen bonds in the reactive loop to the level
determined for SFTI-1. A previous study also reported that
hydrogen bonds of the side loop, in particular the one formed
between carboxylic oxygen of Asp14 and the Gly2 amide, were
necessary to provide rigidity to the SFTI-1 reactive loop [20].
Consequently, this resulted in a reactive loop that closely aligned
with the SFTI-1 starting structure both in terms of conformation
(Figure 2A) and structural stability (Figure 2B and C). Consistent
with a highly rigid scaffold, koff was found to be 0.03160.010 s
-1
with a calculated second order rate constant (koff/Ki) of
8.036108 M21 s21 (Figure 4), suggesting that SFTI-FCQR
Asn14 binding to KLK4 is diffusion controlled. Collectively,
these findings indicate that residue 14 of the side loop is
instrumental for maintaining conformational stability of the
SFTI reactive loop, a requirement for potent standard
mechanism inhibition.
SFTI-FCQR Asn14 is a selective KLK4 inhibitor
Screening SFTI-FCQR Asn14 against a panel of serine protease
targets revealed that this variant was more selective than SFTI-
FCQR Asp14. The most closely related enzyme to KLK4 is
KLK14 with 85% sequence identity within 5 A˚ of the catalytic
triad, while trypsin is a high affinity target for SFTI-1. Although
SFTI-FCQR Asn14 more potently inhibited KLK14 and trypsin,
the relative increase in inhibition was only six-fold and two-fold
respectively, compared to 125-fold improvement for KLK4
(Table 2). This likely reflects that increasing hydrogen bonds,
and therefore binding loop rigidity, produces a more potent
inhibitor in general. Matriptase, thrombin and a-chymotrypsin
which are also inhibited by SFTI-1, showed no inhibition with
SFTI-FCQR Asn14 at 10,000 nM.
Further, it has been demonstrated that amidolytic inhibition of a
small peptide substrate does not necessarily equate to proteolytic
inhibition. For example, SFTI-1 inhibits KLK4 in amidolytic
assays (IC50 = 221610.1 nM) but not in fibrinogen digestion
assays with 2 mM inhibitor [16]. Consequently, the ability of
Figure 3. Relationship between Ki and number of internal
hydrogen bonds. Plot of the average number of internal (circles),
intermolecular (squares) and total (triangles) hydrogen bonds of SFTI-
FCQR variants (Asn14, Tyr14, Lys14, Asp14, Gly14, Ala14 and Ser14) from
Table 1 versus Morrison Ki values from Table 2.
doi:10.1371/journal.pone.0019302.g003
Figure 4. Assessment of koff for SFTI-FCQR Asn14. Lag phases and
steady state for inhibitor binding to KLK4: (A) uninhibited reaction
progress (B) simultaneous addition of substrate and inhibitor (C)
preformed enzyme inhibitor complex. The koff rate was calculated
graphically from the absolute difference between the steady states
at y = zero. Rates shown are the average of three independent
experiments.
doi:10.1371/journal.pone.0019302.g004
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SFTI-FCQR Asn14 to inhibit proteolysis of fibrinogen by KLK4,
KLK12, KLK14 and trypsin was assessed. KLK4 proteolysis was
blocked at inhibitor concentrations as low as 62.5 nM for SFTI-
FCQR Asn14 compared to 250 nM for SFTI-FCQR Asp14, with
more robust inhibition of degradation of the KLK4-preferred
fibrinogen a-chain (Figure 5A–B). No inhibition of KLK12,
KLK14 or trypsin fibrinogen proteolysis by SFTI-FCQR Asn14
occurred up to 10,000 nM (Figure 5C–F).
Figure 5. Selective inhibition of serine protease proteolytic activity by SFTI-FCQR Asn14. Examination of fibrinogen proteolysis by trypsin
and kallikreins by SDS-PAGE. Bands were visualised with Coomassie blue staining after resolving on 10% polyacrylamide gels. Images are
representative of three separate experiments. Inhibition of KLK4 proteolytic activity by (A) SFTI-FCQR Asp14 and (B) SFTI-FCQR Asn14. Inhibition of
trypsin proteolytic activity by (C) SFTI-1 and (D) SFTI-FCQR Asn14. Inhibition of proteolytic activity of (F) KLK12 and (F) KLK14 by SFTI-FCQR Asn14.
doi:10.1371/journal.pone.0019302.g005
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SFTI-FCQR Asn14 is stable in culture with prostate cancer
cells
Previous evaluation of SFTI-FCQR Asp14 stability in culture
with prostate cancer cells revealed that it was highly resistant to
breakdown [16]. Whether replacing Asp14 with Asn markedly
altered inhibitor stability in a cellular environment was assessed by
calculating the half-life of SFTI-FCQR Asn14. Additionally, the
SFTI-FCQR Lys14 half-life was determined given that this variant
seemed to be degraded in competitive kinetic assays (see above).
For SFTI-FCQR Asn14, inhibition of KLK4 gradually declined
over time indicating a slow rate of decay that was comparable
across each cell line (figure 6A). Despite an average reduction in
stability compared to SFTI-FCQR Asp14, a half-life 55–70 hours
is still well above the expected clearance time for peptide-based
therapeutics in vivo. Further, in agreement with previous
observations, SFTI-FCQR Lys14 was rapidly degraded with two-
thirds of the initial activity lost within the first 24 hr (figure 6B).
SFTI-FCQR Asn14 is bioavailable in mice when
administered by intraperitoneal perfusion
While other BBIs are readily bioavailable [45] whether this
applies to SFTI-1 or previously produced variants is yet to be
determined. To establish the pharmacokinetic profile of SFTI-
FCQR Asn14, the inhibitor was delivered via intravenous (IV),
intraperitoneal (IP) and oral routes to BALB/c mice before serum
samples taken over time were quantified by LC-MS. Orally
delivered SFTI-FCQR Asn14 did not result in detectable levels of
inhibitor in serum. In contrast IV and IP administered SFTI-
FCQR Asn14 at a dosage of 3 mg/kg had a serum half-life of 25–
28 mins with a residual inhibition concentration of 10.060.8 nM
after 4 hours irrespective of delivery route (Figure 7).
Discussion
This study has shown that when re-engineering a canonical
serine protease inhibitor preserving binding loop rigidity and
conformation is essential to maintain high binding affinity. Indeed,
inhibitor variants with more frequent internal hydrogen bonds in
silico correlated with more potent inhibition in vitro, emphasising
their role in tight binding complexes. This guided production of an
inhibitor with 125-fold improved potency for KLK4 and
enhanced selectivity over off-target proteases, including closely
related KLKs. Further, SFTI-FCQR Asn14 was stable in a cancer
cell milieu and bioavailable by intraperitoneal perfusion in mice,
making it an attractive candidate for further therapeutic
development.
The suitability of SFTI as a generic scaffold for inhibitor design
and its properties for maintaining structural integrity within a cell
environment have previously been discussed in detail [4,16].
Although SFTI-FCQR Asn14 was less stable than SFTI-FCQR
Asp14 in culture with prostate cancer cells, it was sufficiently
resistant to degradation, highlighting the robustness of the SFTI
scaffold. The fact that SFTI-FCQR Asn14 was also bioavailable by
IP indicates that the inhibitor had the ability to diffuse across
tissues in vivo. This suggests that using a slow release depot implant
is a viable mode of delivery. Alternatively there are numerous
methods available for improving the retention of peptide drugs as
previously reviewed [4]. Most notably, MD analysis indicated that
Ile10 did not make contact with KLK4 and is positioned to provide
an anchoring point for PEGylation [46] unlikely to markedly affect
inhibitory properties.
Figure 6. Stability of SFTI variants in contact with prostate
cancer cells in vitro. Residual activity of (A) SFTI-FCQR Asn14 and (B)
SFTI-FCQR Lys14 in cell culture media from prostate cancer cells treated
with a single dose of inhibitor. Endogenous inhibitors were removed by
boiling and centrifugation. Stability was assessed against LNCaP (closed
circles), 22Rv1 (triangles), and PC3 cells (open circles). Data are mean 6
SEM from three experiments in triplicate.
doi:10.1371/journal.pone.0019302.g006
Figure 7. Bioavailability of SFTI-FCQR Asn14 in mice. Serum
levels of SFTI-FCQR Asn14 administered at 3 mg/kg via the intravenous
(IV), intraperitoneal (IP) routes in mice. Serum half life was 25-28
minutes with 10.060.8 nM inhibitor serum levels at 4 hours. The data is
expressed as mean 6 SEM (IV, n = 3; IP, n = 2).
doi:10.1371/journal.pone.0019302.g007
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Producing potent and selective standard mechanism inhibitors
depends on fully realizing the highly conserved and successful
structural features of the canonical loop. These inhibitors share
two important properties. First, their reactive sites occur in
constrained binding loops with similar structure and conformation
[25]. Second, rigidity is maintained by intrinsic structural
determinants allowing for positioning the P19 free amine for
peptide bond reformation after the scissile bond is cleaved [30,31].
Structural comparison delineates 19 families of inhibitors (I1-I3,
I7, I8, I10-13, I15-20, I36 and I40) that belong to 13 clans
comprising distinct protein folds and evolutionary origins [25].
The fact that the conformation of the canonical binding loop has
evolved numerous times independently highlights its versatility as a
starting structure for inhibitor design. However, whilst most tight
binding standard mechanism inhibitors with large, flexible contact
surfaces are slow binding, the SFTI scaffold is reduced to a simple
canonical loop allowing for both fast and tight binding.
Strategies to re-engineer serine protease inhibitors commonly
focus on the active site binding b-sheet of the canonical loop. The
previous production of a selective KLK4 inhibitor utilised this
approach by grafting a preferred substrate sequence into the b-
sheet of SFTI-1 [16]. While the importance of canonical loop
rigidity is well appreciated in naturally occurring structures, it has
not received similar attention when modifying these inhibitors for
new targets. The present study focused on restoring the internal
hydrogen bonding network of the SFTI scaffold, generating an
inhibitor with considerably increased affinity. Indeed, modifica-
tions of residue 14 that enhanced internal hydrogen bonding
increased potency of inhibition across all variants assayed in vitro.
This may also explain the modest increase in affinity for trypsin
and KLK14 by SFTI-FCQR Asn14. Consistent with the
importance of residue 14 to hydrogen bonding, a previous study
found that substituting Asp14 for Ala in SFTI-1 resulted in a
marked reduction in potency for trypsin [47]. Thus two
complementary strategies for enhancing inhibitor performance
are evident; re-engineering the active site binding b-sheet of SFTI
is instrumental in achieving selectivity while modulating the
internal hydrogen bonding network engenders increased potency.
Bringing these two components together in SFTI-FCQR Asn14
resulted in an inhibitor rivalling SFTI-1 in terms of potency
without its promiscuity.
The findings presented here are in agreement with a previous in
silico study on SFTI-1 using graph representation [48] to analyse
how various internal hydrogen bonds contribute to structural
rigidity [20]. Similarly, it was observed that the hydrogen bonds
within the side loop were important for maintaining rigidity of the
SFTI-1 reactive loop. The strongest contribution was conferred by
the hydrogen bonding pairs of Asp14-Gly1 followed by Phe12-Gly1
and Phe12-Arg2. Although the findings from both studies closely
align, graph representation is confined to structurally determined
hydrogen bonding patterns. As a result, hydrogen bonds are either
present or absent, preventing prediction of how subtle changes in
these patterns and frequencies will affect binding affinities.
The prominent role of internal hydrogen bonding in maintain-
ing canonical loop rigidity is not only limited to the SFTI scaffold.
The same study by Costa and co-workers showed that hydrogen
bonds are vital for stabilising the binding loop for BBIs (Family
I12) in general [20]. Further, studies on Eglin C (Family I13)
assessed point mutations by NMR and competitive binding assays,
highlighting the relationship between inhibition constants and
hydrogen bonds within the binding loop [49]. In fact the
importance of the internal hydrogen bonding network in
maintaining the conformation of the canonical loop has been
demonstrated structurally across most families of standard
mechanism inhibitors [50]. Preservation of these interactions is a
key, yet often overlooked, property to consider when re-
engineering this class of inhibitors.
In contrast to small-molecule inhibitors with few rotational
bonds, conventional docking and scoring of protein-based
inhibitors and their receptors have markedly lower rates of success
[32]. The alternative is to calculate average binding affinities
across MD trajectories including conformations of many low
energy-state complexes [32]. These methods fail to recapitulate the
most important aspect of standard mechanism serine protease
inhibitors: the conformation and rigidity of the canonical loop
before and after cleavage of the scissile bond as well as during the
acyl-enzyme intermediate. Therefore, it is more effective to use
computer-aided design methods to optimize structural features
supporting the binding loop conformation to more closely replicate
the native starting structure. This study focused on analysing one
of these intrinsic canonical loop properties, namely hydrogen
bonds, to accurately predict relative binding affinities of SFTI
variants. We suggest that this simple approach is generally
applicable as a tool to enhance binding affinity when re-
engineering standard mechanism inhibitors. Used in conjunction
with traditional peptide library screens to sample protease subsite
preferences, this strategy is likely to produce both highly selective
and potent inhibitors.
Author Contributions
Conceived and designed the experiments: JES SJdV CFR JMH. Performed
the experiments: JES SJdV KCS. Analyzed the data: JES SJdV JMH.
Contributed reagents/materials/analysis tools: AMB JMH. Wrote the
paper: JES SJdV AMB JMH.
References
1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin
60: 277–300.
2. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, et al. (1999)
Natural history of progression after PSA elevation following radical prostatec-
tomy. JAMA 281: 1591–1597.
3. Sotiropoulou G, Pampalakis G, Diamandis EP (2009) Functional roles of human
kallikrein-related peptidases. J Biol Chem 284: 32989–32994.
4. Swedberg JE, de Veer SJ, Harris JM (2010) Natural and engineered kallikrein
inhibitors: an emerging pharmacopoeia. Biol Chem 391: 357–374.
5. Goettig P, Magdolen V, Brandstetter H (2010) Natural and synthetic inhibitors
of kallikrein-related peptidases (KLKs). Biochimie, (In press) DOI: 10.1016/
j.biochi.2010.06.022.
6. Lawrence MG, Lai J, Clements JA (2010) Kallikreins on steroids: structure,
function, and hormonal regulation of prostate-specific antigen and the extended
kallikrein locus. Endocr Rev 31: 407–446.
7. Xi Z, Klokk TI, Korkmaz K, Kurys P, Elbi C, et al. (2004) Kallikrein 4 is a
Predominantly Nuclear Protein and Is Overexpressed in Prostate Cancer.
Cancer Res 64: 2365–2370.
8. Veveris-Lowe TL, Lawrence MG, Collard RL, Bui L, Herington AC, et al.
(2005) Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated
with the loss of E-cadherin and an epithelial-mesenchymal transition
(EMT)-like effect in prostate cancer cells. Endocr Relat Cancer 12: 631–
643.
9. Obiezu CV, Michael IP, Levesque MA, Diamandis EP (2006) Human kallikrein
4: enzymatic activity, inhibition, and degradation of extracellular matrix
proteins. Biol Chem 387: 749–759.
10. Matsumura M, Bhatt AS, Andress D, Clegg N, Takayama TK, et al. (2005)
Substrates of the prostate-specific serine protease prostase/KLK4 defined by
positional-scanning peptide libraries. Prostate 62: 1–13.
11. Beaufort N, Debela M, Creutzburg S, Kellermann J, Bode W, et al. (2006)
Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation
system: hK4 regulates the structure and functions of the urokinase-type
plasminogen activator receptor (uPAR). Biol Chem 387: 217–222.
12. Mize GJ, Wang W, Takayama TK (2008) Prostate-specific kallikreins-2 and -4
enhance the proliferation of DU-145 prostate cancer cells through protease-
activated receptors-1 and -2. Mol Cancer Res 6: 1043–1051.
Serine Protease Inhibitor Engineering
PLoS ONE | www.plosone.org 10 April 2011 | Volume 6 | Issue 4 | e19302
13. Greenberg DL, Mize GJ, Takayama TK (2003) Protease-activated receptor
mediated RhoA signaling and cytoskeletal reorganization in LNCaP cells.
Biochemistry 42: 702–709.
14. Ramsay AJ, Dong Y, Hunt ML, Linn M, Samaratunga H, et al. (2008)
Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via
protease-activated receptors (PARs). KLK4 and PAR-2 are co-expressed during
prostate cancer progression. J Biol Chem 283: 12293–12304.
15. Gao J, Collard RL, Bui L, Herington AC, Nicol DL, et al. (2007) Kallikrein 4 is
a potential mediator of cellular interactions between cancer cells and osteoblasts
in metastatic prostate cancer. Prostate 67: 348–360.
16. Swedberg JE, Nigon LV, Reid JC, de Veer SJ, Walpole CM, et al. (2009)
Substrate-guided design of a potent and selective kallikrein-related peptidase
inhibitor for kallikrein 4. Chem Biol 16: 633–643.
17. Luckett S, Garcia RS, Barker JJ, Konarev AV, Shewry PR, et al. (1999) High-
resolution structure of a potent, cyclic proteinase inhibitor from sunflower seeds.
J Mol Biol 290: 525–533.
18. Legowska A, Debowski D, Lesner A, Wysocka M, Rolka K (2009) Introduction
of non-natural amino acid residues into the substrate-specific P1 position of
trypsin inhibitor SFTI-1 yields potent chymotrypsin and cathepsin G inhibitors.
Bioorg Med Chem 17: 3302–3307.
19. Long YQ, Lee SL, Lin CY, Enyedy IJ, Wang S, et al. (2001) Synthesis and
evaluation of the sunflower derived trypsin inhibitor as a potent inhibitor of the
type II transmembrane serine protease, matriptase. Bioorg Med Chem Lett 11:
2515–2519.
20. Costa JR, Yaliraki SN (2006) Role of rigidity on the activity of proteinase
inhibitors and their peptide mimics. J Phys Chem B 110: 18981–18988.
21. Korsinczky ML, Schirra HJ, Rosengren KJ, West J, Condie BA, et al. (2001)
Solution structures by 1H NMR of the novel cyclic trypsin inhibitor SFTI-1
from sunflower seeds and an acyclic permutant. J Mol Biol 311: 579–591.
22. Hubbard SJ, Campbell SF, Thornton JM (1991) Molecular recognition.
Conformational analysis of limited proteolytic sites and serine proteinase protein
inhibitors. J Mol Biol 220: 507–530.
23. Madala PK, Tyndall JD, Nall T, Fairlie DP (2010) Update 1 of: Proteases
Universally Recognize Beta Strands In Their Active Sites. Chem Rev: DOI:
10.1021/cr900368a.
24. Marx UC, Korsinczky ML, Schirra HJ, Jones A, Condie B, et al. (2003)
Enzymatic cyclization of a potent bowman-birk protease inhibitor, sunflower
trypsin inhibitor-1, and solution structure of an acyclic precursor peptide. J Biol
Chem 278: 21782–21789.
25. Rawlings ND, Tolle DP, Barrett AJ (2004) Evolutionary families of peptidase
inhibitors. Biochem J 378: 705–716.
26. Laskowski M, Qasim MA (2000) What can the structures of enzyme-inhibitor
complexes tell us about the structures of enzyme substrate complexes? Biochim
Biophys Acta 1477: 324–337.
27. Laskowski M, Jr., Kato I (1980) Protein inhibitors of proteinases. Annu Rev
Biochem 49: 593–626.
28. Haberkorn U, Eisenhut M, Altmann A, Mier W (2008) Endoradiotherapy with
peptides - status and future development. Curr Med Chem 15: 219–234.
29. Shaw GL, Davis B, Keeler J, Fersht AR (1995) Backbone dynamics of
chymotrypsin inhibitor 2: effect of breaking the active site bond and its
implications for the mechanism of inhibition of serine proteases. Biochemistry
34: 2225–2233.
30. Radisky ES, Koshland DE, Jr. (2002) A clogged gutter mechanism for protease
inhibitors. Proc Natl Acad Sci U S A 99: 10316–10321.
31. Zakharova E, Horvath MP, Goldenberg DP (2009) Structure of a serine protease
poised to resynthesize a peptide bond. Proc Natl Acad Sci U S A 106:
11034–11039.
32. Sousa SF, Fernandes PA, Ramos MJ (2006) Protein-ligand docking: current
status and future challenges. Proteins 65: 15–26.
33. Cozzini P, Kellogg GE, Spyrakis F, Abraham DJ, Costantino G, et al. (2008)
Target flexibility: an emerging consideration in drug discovery and design. J Med
Chem 51: 6237–6255.
34. Diaz N, Suarez D (2008) Molecular dynamics simulations of the active matrix
metalloproteinase-2: positioning of the N-terminal fragment and binding of a
small peptide substrate. Proteins 72: 50–61.
35. Pang YP, Vummenthala A, Mishra RK, Park JG, Wang S, et al. (2009) Potent
new small-molecule inhibitor of botulinum neurotoxin serotype A endopeptidase
developed by synthesis-based computer-aided molecular design. PLoS One 4:
e7730.
36. Anderson JA, Lorenz CD, Travesset A (2008) General purpose molecular
dynamics simulations fully implemented on graphics processing units. J Comput
Phys 227: 5342–5359.
37. Harvey M, Giupponi G, De Fabritiis G (2009) ACEMD: Accelerated molecular
dynamics simulations in the microseconds timescale. J Chem Theory Comput 5:
1632.
38. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, et al. (2005) Scalable
molecular dynamics with NAMD. J Comput Chem 26: 1781–1802.
39. Guex N, Peitsch MC (1997) SWISS-MODEL and the Swiss-PdbViewer: an
environment for comparative protein modeling. Electrophoresis 18: 2714–2723.
40. Krieger E, Koraimann G, Vriend G (2002) Increasing the precision of
comparative models with YASARA NOVA–a self-parameterizing force field.
Proteins 47: 393–402.
41. Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics.
J Mol Graph 14: 33–38,27-38.
42. Abbenante G, Leung D, Bond T, Fairlie DP (2000) An efficient Fmoc strategy
for the rapid synthesis of peptide para-nitroanilides. Lett Pept Sci 7: 347–351.
43. Morrison JF, Walsh CT (1988) The behavior and significance of slow-binding
enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 61: 201–301.
44. Baici A, Gyger-Marazzi M (1982) The slow, tight-binding inhibition of cathepsin
B by leupeptin. A hysteretic effect. Eur J Biochem 129: 33–41.
45. Kennedy AR (1998) Chemopreventive agents: protease inhibitors. Pharmacol
Ther 78: 167–209.
46. Jain S, Hreczuk-Hirst D, Laing P, Gregoriadis G (2004) Polysialylation: the
natural way to improve the stability and pharmacokinetics of protein and
peptide drugs. Drug Deliv Systems Sci 4: 3–10.
47. Daly NL, Chen Y-K, Foley FM, Bansal PS, Bharathi R, et al. (2006) The
absolute structural requirement for a proline in the P39-position of Bowman-Birk
protease inhibitors is surmounted in the minimized SFTI-1 scaffold. J Biol Chem
281: 23668–23675.
48. Jacobs DJ, Rader AJ, Kuhn LA, Thorpe MF (2001) Protein flexibility
predictions using graph theory. Proteins 44: 150–165.
49. Heinz DW, Hyberts SG, Peng JW, Priestle JP, Wagner G, et al. (1992) Changing
the inhibitory specificity and function of the proteinase inhibitor eglin c by site-
directed mutagenesis: functional and structural investigation. Biochemistry 31:
8755–8766.
50. Krowarsch D, Cierpicki T, Jelen F, Otlewski J (2003) Canonical protein
inhibitors of serine proteases. Cell Mol Life Sci 60: 2427–2444.
51. Descours A, Moehle D, Renard A, Robinson JA (2002) A New Family of Beta-
Hairpin Mimetics Based on a Trypsin Inhibitor from Sunflower Seeds.
ChemBioChem 3: 318–323.
Serine Protease Inhibitor Engineering
PLoS ONE | www.plosone.org 11 April 2011 | Volume 6 | Issue 4 | e19302
